Drug
MEDI9929
MEDI9929 is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_2
2
67%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_2
Effects of Anti-TSLP in Patients With Asthma
NCT02698501
completedphase_2
Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis
NCT02525094
completedphase_1
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects
NCT01913028
Clinical Trials (3)
Showing 3 of 3 trials
NCT02698501Phase 2
Effects of Anti-TSLP in Patients With Asthma
NCT02525094Phase 2
Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis
NCT01913028Phase 1
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3